Business
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
WATERTOWN, Mass., April 08, 2025--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":732,"url":"https://media.zenfs.com/en/business-wire.com/77410662b411542718223d0a206d53bf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Fy9OtOJOE_Y35.7IxMjtpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/77410662b411542718223d0a206d53bf","width":960,"height":321},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fowNVo5r3eOjWVjqs4se3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/77410662b411542718223d0a206d53bf","width":1200,"height":401}},"lazy":false},{"type":"text","content":"WATERTOWN, Mass., April 08, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV) has been accepted for an oral presentation as an ePoster at the European Society of Clinical Microbiology & Infectious Diseases Global 2025 (ESCMID, formerly ECCMID) being held April 11-15, 2025 in Vienna, Austria.","length":589,"tagName":"p"},{"type":"text","content":"The oral ePoster presentation will include results from a Phase 2a human challenge study of EDP-323, a first-in-class, oral, non-nucleoside small-molecule inhibitor of the RSV polymerase (L-protein), which were announced in September 2024 and highlight new data on respiratory mucus production.","length":294,"tagName":"p"},{"type":"text","content":"ePoster Title: "EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study"ePoster Number: E0289Abstract Number: 04019Date and Time: April 13, 2025, 8:30 a.m. CEST/ 2:30 a.m. EDTSession Location: Arena 1Session Title: Novel Approaches to Antiviral TherapyPresenter: John P. DeVincenzo, M.D.","length":425,"tagName":"p"},{"type":"text","content":"The scientific program for ESCMID Global 2025 can be found here.","length":64,"tagName":"p"},{"type":"text","content":"About Enanta Pharmaceuticals, Inc.","...